Nothing Special   »   [go: up one dir, main page]

DE60127143D1 - Bispezifische Antikörper gegen CD19 und CD16 und deren Verwendung - Google Patents

Bispezifische Antikörper gegen CD19 und CD16 und deren Verwendung

Info

Publication number
DE60127143D1
DE60127143D1 DE60127143T DE60127143T DE60127143D1 DE 60127143 D1 DE60127143 D1 DE 60127143D1 DE 60127143 T DE60127143 T DE 60127143T DE 60127143 T DE60127143 T DE 60127143T DE 60127143 D1 DE60127143 D1 DE 60127143D1
Authority
DE
Germany
Prior art keywords
antibodies
polynucleotides
vectors
human
antibodies against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60127143T
Other languages
English (en)
Other versions
DE60127143T2 (de
Inventor
Gall Fabrice Le
M Sergey Kipriyanov
Gerhard Moldenhauer
Melvyn Little
Bjoern Cochlovius
J Holger Schaefer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affimed GmbH
Original Assignee
Affimed Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affimed Therapeutics AG filed Critical Affimed Therapeutics AG
Publication of DE60127143D1 publication Critical patent/DE60127143D1/de
Application granted granted Critical
Publication of DE60127143T2 publication Critical patent/DE60127143T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60127143T 2001-11-14 2001-11-14 Bispezifische Antikörper gegen CD19 und CD16 und deren Verwendung Expired - Lifetime DE60127143T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01127061A EP1314741B1 (de) 2001-11-14 2001-11-14 Bispezifische Antikörper gegen CD19 und CD16 und deren Verwendung

Publications (2)

Publication Number Publication Date
DE60127143D1 true DE60127143D1 (de) 2007-04-19
DE60127143T2 DE60127143T2 (de) 2007-11-15

Family

ID=8179236

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60127143T Expired - Lifetime DE60127143T2 (de) 2001-11-14 2001-11-14 Bispezifische Antikörper gegen CD19 und CD16 und deren Verwendung

Country Status (8)

Country Link
US (1) US20050089519A1 (de)
EP (1) EP1314741B1 (de)
JP (1) JP4373788B2 (de)
AT (1) ATE356149T1 (de)
AU (1) AU2002356601A1 (de)
DE (1) DE60127143T2 (de)
ES (1) ES2283368T3 (de)
WO (1) WO2003048209A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
EP1354600A1 (de) * 2002-04-19 2003-10-22 Affimed Therapeutics AG Antikörperkombination verwendbar für Tumortherapie
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
SI1912675T1 (sl) 2005-07-25 2014-07-31 Emergent Product Development Seattle, Llc zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20
EP3805269A1 (de) 2006-06-12 2021-04-14 Aptevo Research and Development LLC Einkettige, multivalente bindungsproteine mit effektorfunktion
DK2383297T5 (da) 2006-08-14 2022-07-04 Xencor Inc Optimerede antistoffer rettet mod CD19
PL2066349T3 (pl) 2006-09-08 2012-09-28 Medimmune Llc Humanizowane przeciwciała anty-CD19 i ich zastosowanie w leczeniu nowotworów, transplantacjach i leczeniu chorób autoimmunologicznych
DK1903115T3 (da) * 2006-09-22 2011-05-23 Wacker Chemie Ag Fremgangsmåde til fermentativ fremstilling af antistoffer
EP2014680A1 (de) * 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Rekombinante, einkettige, trivalente trispezifische oder bispezifische Antikörperderivate
DE102007041834A1 (de) * 2007-09-03 2009-03-05 Siemens Ag Arzneimittel zur Behandlung eines Karzinoms
CN102099377A (zh) 2008-04-11 2011-06-15 新兴产品开发西雅图有限公司 Cd37免疫治疗剂及其与双功能化学治疗剂的联合
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
WO2012066058A1 (en) 2010-11-16 2012-05-24 Boehringer Ingelheim International Gmbh Agents and methods for treating diseases that correlate with bcma expression
CA2820782A1 (en) * 2010-12-10 2012-06-14 Merck Patent Gmbh Bispecific aptamers mediating tumour cell lysis
EP2729488A4 (de) * 2011-07-06 2015-01-14 Medimmune Llc Verfahren zur herstellung multimerer polypeptide
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
EP2762496A1 (de) 2013-02-05 2014-08-06 EngMab AG Verfahren zur Auswahl von Antikörpern gegen BCMA
WO2014122143A1 (en) 2013-02-05 2014-08-14 Engmab Ag Method for the selection of antibodies against bcma
EP2789630A1 (de) 2013-04-09 2014-10-15 EngMab AG Bispezifische Antikörper gegen CD3e und ROR1
US11952421B2 (en) 2014-10-09 2024-04-09 Bristol-Myers Squibb Company Bispecific antibodies against CD3EPSILON and ROR1
US11000603B2 (en) 2015-04-14 2021-05-11 Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. Multi-specific binding conjugate, related pharmaceutical compositions and use
JP6682632B2 (ja) 2015-08-03 2020-04-15 エンクマフ エスアーエールエル Ｂｃｍａに対するモノクローナル抗体
MA44909A (fr) 2015-09-15 2018-07-25 Acerta Pharma Bv Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
EA201890613A1 (ru) 2015-09-21 2018-10-31 Аптево Рисёрч Энд Девелопмент Ллс Полипептиды, связывающие cd3
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
PE20181089A1 (es) * 2015-10-02 2018-07-09 Hoffmann La Roche Anticuerpos anti-cd19 humano con alta afinidad
US11525009B2 (en) 2016-06-22 2022-12-13 Benhealth Biopharmaceutic (Shenzhen) Co. Ltd. Bispecific antibody and antibody conjugate for tumor therapy and use thereof
BR112019008426A2 (pt) 2016-11-02 2019-09-03 Engmab Sarl anticorpo biespecífico contra bcma e cd3 e um fármaco imunológico para uso combinado no tratamento de mieloma múltiplo
DK3589655T3 (da) * 2017-02-28 2022-11-28 Affimed Gmbh Tandem diabody til cd16a målrettet nk-celle optagelse
BR112020011810A2 (pt) * 2017-12-12 2020-11-17 Macrogenics, Inc. molécula de ligação cd16 x antígeno de doença, composição farmacêutica, uso da composição farmacêutica, e método para o tratamento de uma doença
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2020089437A1 (en) 2018-10-31 2020-05-07 Engmab Sàrl Combination therapy
WO2020097155A1 (en) 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases
JP2022515543A (ja) 2018-12-30 2022-02-18 エフ．ホフマン－ラ ロシュ アーゲー 抗ウサギｃｄ１９抗体および使用方法
RU2738802C1 (ru) * 2019-08-21 2020-12-17 Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" Определяющие комплементарность участки для связывания cd3 и содержащая их биспецифическая антигенсвязывающая молекула
US20240101677A1 (en) 2021-01-27 2024-03-28 Innovent Biologics (Suzhou) Co., Ltd. Single-domain antibody against cd16a and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843708A (en) * 1988-01-05 1998-12-01 Ciba-Geigy Corporation Chimeric antibodies
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
AU690528B2 (en) * 1992-12-04 1998-04-30 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
HUP9900956A2 (hu) * 1998-04-09 2002-04-29 Aventis Pharma Deutschland Gmbh. Egyláncú, több antigéntkötőhely kialakítására képes molekulák, előállításuk és alkalmazásuk
DE19819846B4 (de) * 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte

Also Published As

Publication number Publication date
JP2005517392A (ja) 2005-06-16
ATE356149T1 (de) 2007-03-15
WO2003048209A1 (en) 2003-06-12
ES2283368T3 (es) 2007-11-01
AU2002356601A1 (en) 2003-06-17
JP4373788B2 (ja) 2009-11-25
DE60127143T2 (de) 2007-11-15
EP1314741A1 (de) 2003-05-28
EP1314741B1 (de) 2007-03-07
US20050089519A1 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
DE60127143D1 (de) Bispezifische Antikörper gegen CD19 und CD16 und deren Verwendung
BR0209989A (pt) Plataformas baseadas em cromossomas
NO20005296D0 (no) CD19xCD3-spesifikke polypeptider og anvendelser derav
NO346167B1 (no) Humanisert, glykoomkonstruert Type II anti-CD20 antistoff og anvendelse derav, samt vertscelle og farmasøytisk sammensetning
WO2003048334A3 (en) Immunocytokines with modulated selectivity
ATE517125T1 (de) ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN
ATE429450T1 (de) Chimärische dr4 antikörper und ihre verwendung
DE69031410D1 (de) Monoklonale Antikörper gegen den humanen alpha/beta-T-Zellenrezeptor, ihre Herstellung und Verwendung
AU706584C (en) Immunoglobulin variants
WO2006076691A3 (en) Irta-2 antibodies and their uses
ATE551363T1 (de) Verwendung von antikörper gegen interleukin-4 rezeptor und deren zusammensetzungen
DK0980429T3 (da) Human Toll-lignende receptorproteiner, beslægtede reagenser og fremgangsmåder
CY1110505T1 (el) Ανθρωπινα αντισωματα dr4 και χρησεις αυτων
DE69520149D1 (de) Tie-2 ligande, verfahren zu ihrer herstellung, und ihre anwendungen
DE602004007257D1 (de) Hydroxy-diaryl-carbaldehyd- oxim-verbindungen und deren verwendung als oestrogenwirksame substanzen
ATE322288T1 (de) Zusammensetzungen zur immunisierung sowie deren verwendung
WO2005056606A3 (en) Optimized antibodies that target the epidermal growth factor receptor
BRPI0415361A (pt) antagonistas do receptor muscarìnico de acetilcolina
DE69724428D1 (de) Humanisierte antikörper die an das gleiche antigen wie antikörper nr-lu-13 binden und deren verwendung in "pretargeting" verfahren
ATE435872T1 (de) Anti-interleukin-1 rezeptor antikörper und deren verwendung
WO2005097185A3 (en) Irta-5 antibodies and their uses
BRPI0417215A (pt) antagonistas de receptor muscarìnico de acetilcolina m3
DE60038739D1 (de) Somatostatin analoge, deren radiomarkierte derivate und deren verwendung
DE69504959D1 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
ATE157401T1 (de) Monoklonale antikörper gegen humanes ige

Legal Events

Date Code Title Description
8364 No opposition during term of opposition